The clinical significance of cereblon expression in multiple myeloma

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 23-28

  Schuster, Steven R ^a   Kortuem, K Martin ^b   Zhu, Yuan Xiao ^b   Braggio, Esteban ^b   Shi, Chang Xin ^b   Bruins, Laura A ^b   Schmidt, Jessica E ^b   Ahmann, Greg ^b   Kumar, Shaji ^c   Rajkumar, S Vincent ^c   Mikhael, Joseph ^b   LaPlant, Betsy ^c   Champion, Mia D ^b   Laumann, Kristina ^c   Barlogie, Bart ^d   Fonseca, Rafael ^b   Bergsagel, P Leif ^b   Lacy, Martha ^c   Stewart, A Keith ^b  

^a University of Colorado Health   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

Biological markers; Cereblon; Gene expression profiling; Immunomodulatory drugs; Multiple myeloma

Indexed keywords

BORTEZOMIB; CEREBLON; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME 3; CONTROLLED STUDY; CRBN GENE; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE EXPRESSION; GENE LOCATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84890565990     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.015     Document Type: Article

References (24)

1. Rajkumar S.V. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011, 8:479-491.
2. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999, 5:582-585.
3. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
4. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
5. Escoubet-Lozach L., Lin I.L., Jensen-Pergakes K., Brady H.A., Gandhi A.K., Schafer P.H., et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
6. Shaffer A.L., Emre N.C., Lamy L., Ngo V.N., Wright G., Xiao W., et al. IRF4 addiction in multiple myeloma. Nature 2008, 454:226-231.
7. Li S., Pal R., Monaghan S.A., Schafer P., Ouyang H., Mapara M., et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117:5157-5165.
8. Lopez-Girona A., Heintel D., Zhang L.-H., Mendy D., Gaidarova S., Brady H., et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154:325-336.
9. Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wier S., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
10. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
11. Broyl A., Kuiper R., van Duin M., van der Holt B., el Jarari L., Bertsch U., et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013, 121:624-627.
12. Heintel D., Rocci A., Ludwig H., Bolomsky A., Caltagirone S., Schreder M., et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013, 161:695-700.
13. Egan J., Kortuem K.M., Shi C.-X., Schmidt J., Craig D., Carpten J., et al. The myeloma genome in drug refractory extra-medullary disease identifies mutations in proteasome, cereblon and glucocorticoid pathways. ASH Annu Meet Abst 2012, 120:3968.
14. Neri P., Belch A.R., Johnson J., Gratton K.J., Ren L., Duggan P., et al. A miRNA risk score for the prediction of response to lenalidomide in multiple myeloma (MM) patients. ASH Annu Meet Abst 2011, 118:987.
15. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
16. Wiernik P.H., Lossos I.S., Tuscano J.M., Justice G., Vose J.M., Cole C.E., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
17. Witzig T.E., Wiernik P.H., Moore T., Reeder C., Cole C., Justice G., et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009, 27:5404-5409.
18. Lacy M.Q., Hayman S.R., Gertz M.A., Dispenzieri A., Buadi F., Kumar S., et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27:5008-5014.
19. Lacy M.Q., Hayman S.R., Gertz M.A., Short K.D., Dispenzieri A., Kumar S., et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24:1934-1939.
20. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
21. Bergsagel P.L., Kuehl W.M., Zhan F., Sawyer J., Barlogie B., Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106:296-303.
22. Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003, 102:2562-2567.
23. Lacy M.Q., Allred J.B., Gertz M.A., Hayman S.R., Short K.D., Buadi F., et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011, 118:2970-2975.
24. Hernandez-Ilizaliturri F.J., Deeb G., Zinzani P.L., Pileri S.A., Malik F., Macon W.R., et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011, 117:5058-5066.